This Week Last Year in Medtech: May 14-20
18 May 2023
INDDrug Approval
Medtronic Wins FDA Nod for Onyx Frontier DES
The Dublin-based company said the device is the latest innovation in the Resolute DES family.
Babson Has Friends in High Places
The blood-testing startup that's trying to succeed where Theranos failed has expanded its strategic partnership with the sixth largest medtech company in the world.
MannKind Acquires Wearable Insulin Device from Zealand Pharma
The Danbury, CT-based company said it was picking up the V-Go wearable $10 million.
An At-Home Collection Device for Diabetes Risk Testing
A prospective study will evaluate the long-term performance of a closed-loop algorithm with Medtronic’s investigative rechargeable neurostimulator.
Stryker Is Smart to Pursue This Type of Reimbursement
CMS recently established a new code for outpatient hospitals and ambulatory surgery centers to report the insertion of Stryker's InSpace balloon implant.
Medtronic Touts Cusp Overlap Technique in TAVR
Mid-term results of the Optimize PRO clinical study underscores predictability and control using the cusp overlap technique during transcatheter aortic valve replacement (TAVR) with Medtronic TAVR devices.
The Robot Will Do Your Angioplasty Now
Study results show promise for robotic coronary angioplasties using Robocath's R-One robot.
J&J MedTech Lands Clearance for Inhance Shoulder System
This clearance is in addition to the system’s already cleared use in anatomic shoulder arthroplasty.
Abbott Heart Valve Data Shines at EuroPCR
The data support the use of the company's TriClip tricuspid heart valve repair device, and Navitor, Abbott's transcatheter aortic valve implantation system.
NeuroOne’s Bid for Long-term Use of Evo sEEG Shot Down by FDA
The Eden Praire, MN-based company called the decision disappointing but said it would collect more data and submit for a Special 510 (k).
Has Medtech Shifted to a Seller's Strike?
Analyst says both the number and dollar volume of medtech M&A deals are likely to drop in 2022, compared to 2021.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.